Pharma

Your Article Summary

See Latest Articles

Copaxone is Approved for Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis
Teva Pharmaceutical Industries, 02/05/09

Teva Pharmaceutical Industries Ltd. announced that the Medicines and Healthcare products Regulatory Agency has approved an expanded label for COPAXONE to include the treatment of patients with clinical isolated syndrome suggestive of multiple sclerosis. This approval includes 24 EU member countries that take part in the MHRA "mutual recognition procedure". A similar application for the expanded COPAXONE label is currently under review by the U.S. Food and Drug Administration.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals